The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Phosphoinositide 3-Kinase p110β Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development
Open accessAbstract
The phosphoinositide 3-kinase p110β subunit has noncatalytic functions; its catalytic activity is pertinent to both diabetes and cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mora, A., Lipina, C., Tronche, F., Sutherland, C. D., & Alessi, D. R. (2005) · Biochemical Journal · doi:10.1042/bj20041782 · Cited by 107
RetractedThe evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · cited 1×
“Class IA PI3Ks are activated by either p85 recruitment to phosphorylated RTKs and adaptors such as insulin receptor substrates 1 and 2 (IRS-1 and IRS-2) or by binding to Ras (2).”
BackgroundERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 946
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 823
Oncogenic PI3K deregulates transcription and translation
Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798
Cited by
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Yu, J. S. L., & Cui, W. (2016) · Development · doi:10.1242/dev.137075 · Cited by 1,135
PI3K/AKT signaling pathway and cancer: An updated review
Martini, M., De Santis, M. C., Braccini, L., Gulluni, F., & Hirsch, E. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912836 · Cited by 1,020
Self-citationInterleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases
Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klunker, S., Meyer, N., O’Mahony, L., Palomares, O., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.050 · Cited by 778
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Okkenhaug, K. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095946 · Cited by 446
Bone regeneration and stem cells
Arvidson, K., Abdallah, B. M., Applegate, L. A., Baldini, N., Cenni, E., Gomez-Barrena, E., Granchi, D., Kassem, M., Konttinen, Y. T., Mustafa, K., et al. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01224.x · Cited by 408
PI3Kδ and primary immunodeficiencies
Lucas, C. L., Chandra, A., Nejentsev, S., Condliffe, A. M., & Okkenhaug, K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.93 · Cited by 342
RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
Fritsch, R., de Krijger, I., Fritsch, K., George, R., Reason, B., Kumar, M. S., Diefenbacher, M., Stamp, G., & Downward, J. (2013) · Cell · doi:10.1016/j.cell.2013.04.031 · Cited by 306
Lin, Z., Zhou, P., von Gise, A., Gu, F., Ma, Q., Chen, J., Guo, H., van Gorp, P. R. R., Wang, D.-Z., & Pu, W. T. (2015) · Circulation Research · doi:10.1161/circresaha.115.304457 · Cited by 304
Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases
Vadas, O., Burke, J. E., Zhang, X., Berndt, A., & Williams, R. L. (2011) · Science Signaling · doi:10.1126/scisignal.2002165 · Cited by 299
Novel insights into G protein and G protein-coupled receptor signaling in cancer
O’Hayre, M., Degese, M. S., & Gutkind, J. S. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.01.005 · Cited by 296
Mammalian phosphoinositide kinases and phosphatases
Sasaki, T., Takasuga, S., Sasaki, J., Kofuji, S., Eguchi, S., Yamazaki, M., & Suzuki, A. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.06.001 · Cited by 283
Efficacy of PI3K inhibitors in advanced breast cancer
Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221
Synergy in activating class I PI3Ks
Burke, J. E., & Williams, R. L. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.003 · Cited by 216
Mohammad, S., Ramos, L. S., Buck, J., Levin, L. R., Rubino, F., & McGraw, T. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.289009 · Cited by 59
Yuzugullu, H., Baitsch, L., Von, T., Steiner, A., Tong, H., Ni, J., Clayton, L. K., Bronson, R., Roberts, T. M., Gritsman, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms9501 · Cited by 47
Toward a quantitative understanding of the Wnt/β‐catenin pathway through simulation and experiment
Lloyd‐Lewis, B., Fletcher, A. G., Dale, T. C., & Byrne, H. M. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1221 · Cited by 31
Duewell, B. R., Wilson, N. E., Bailey, G. M., Peabody, S. E., & Hansen, S. D. (2024) · eLife · doi:10.7554/elife.88991.3 · Cited by 2
Duewell, B. R., Wilson, N. E., Bailey, G. M., Peabody, S. E., & Hansen, S. D. (2023) · doi:10.1101/2023.05.01.538969
Metadata
- Authors
- Ciraolo, E., Iezzi, M., Marone, R., Marengo, S., Curcio, C., Costa, C., Azzolino, O., Gonella, C., Rubinetto, C., Wu, H., Dastrù, W., Martin, E. L., Silengo, L., Altruda, F., Turco, E., Lanzetti, L., Musiani, P., Rückle, T., Rommel, C., Backer, J. M., Forni, G., Wymann, M. P., & Hirsch, E.
- Venue
- Science Signaling
- Published
- 2008-09-09
- Volume
- 1
- Issue
- 36
- Pages
- ra3-ra3
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W1991761103
- Cited by
- 269
- References
- 37
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.